Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) CFO Jason Haas purchased 1,000 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $20,000.00. Following the purchase, the chief financial officer owned 62,908 shares in the company, valued at $1,258,160. This trade represents a 1.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Odyssey Therapeutics Stock Performance
Shares of NASDAQ:ODTX traded up $1.03 during midday trading on Monday, hitting $17.45. The company had a trading volume of 426,992 shares. Odyssey Therapeutics, Inc. has a 12 month low of $15.35 and a 12 month high of $20.30.
Recommended Stories
- Five stocks we like better than Odyssey Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
